Royal Bank Of Canada started coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a sector perform rating and a $475.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on REGN. Leerink Swann restated a positive rating and issued a $552.00 target price (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Sanford C. Bernstein restated an outperform rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Piper Jaffray Companies restated an overweight rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Robert W. Baird reiterated a sell rating and set a $408.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 8th. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 16th. They set an outperform rating and a $605.00 price target for the company. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $491.43.

Regeneron Pharmaceuticals (REGN) opened at 433.45 on Thursday. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The firm has a 50 day moving average of $472.80 and a 200-day moving average of $445.37. The stock has a market cap of $45.96 billion, a PE ratio of 43.48 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the business posted $2.82 EPS. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/18/regeneron-pharmaceuticals-inc-regn-now-covered-by-analysts-at-royal-bank-of-canada.html.

In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 99,543 shares of company stock valued at $47,831,369 over the last 90 days. 10.40% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in REGN. Gabelli Funds LLC boosted its stake in shares of Regeneron Pharmaceuticals by 13.3% during the 1st quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock worth $2,635,000 after purchasing an additional 800 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,641 shares of the biopharmaceutical company’s stock worth $2,186,000 after purchasing an additional 1,307 shares during the last quarter. TFS Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $480,000. Toronto Dominion Bank boosted its stake in shares of Regeneron Pharmaceuticals by 57.4% during the 1st quarter. Toronto Dominion Bank now owns 20,540 shares of the biopharmaceutical company’s stock worth $7,958,000 after purchasing an additional 7,487 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its stake in shares of Regeneron Pharmaceuticals by 2.3% during the 1st quarter. NEXT Financial Group Inc now owns 916 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 21 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.